PSA density versus risk stratification for lymphadenectomy-making decision in patients with prostate cancer undergoing radical prostatectomy
- PMID: 21437595
- DOI: 10.1007/s11255-011-9942-9
PSA density versus risk stratification for lymphadenectomy-making decision in patients with prostate cancer undergoing radical prostatectomy
Abstract
Objectives: To determine the value of PSA density as independent predictor for lymph node invasion in order to decide lymphadenectomy in patients undergoing radical prostatectomy.
Patients and methods: We retrospectively analyzed the medical records of 179 patients who undergone radical prostatectomy from January 2001 until September 2010. Studied patients divided in groups regarding the preoperative risk for lymph node metastasis (low risk or not) and PSA density (≤.2 or greater). Age, prostate volume, preoperative PSA, and preoperative Gleason score (≤ 6 or ≥ 7) were estimated as well. We analyze the impact of the above factors in prediction of lymph nodes metastasis after radical prostatectomy.
Results: One patient found to have lymph node invasion out of 48 who stratified as low-risk patients and 1 out of 77 who had PSA density ≤.2. There was a significant correlation between preoperative PSA, PSA density, and risk stratification among patients who had metastasis or not. These findings confirmed in the univariate analysis of these factors. However, in multivariate analysis, PSA density was the only statistically significant predictor.
Conclusion: This is the first study to compare preoperative risk stratification and PSA density as predictors of lymph node metastasis in patients who are planned for radical prostatectomy. PSA density values ≤.2 can predict lymph nodes metastasis in a larger population of patients and consequently can potentially decrease the number of lymphadenectomies during radical prostatectomy procedures.
Similar articles
-
Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.Urology. 1994 Oct;44(4):519-24. doi: 10.1016/s0090-4295(94)80050-2. Urology. 1994. PMID: 7524237 Clinical Trial.
-
Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502
-
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.J Urol. 2004 Nov;172(5 Pt 1):1860-4. doi: 10.1097/01.ju.0000139886.25848.4a. J Urol. 2004. PMID: 15540739
-
Indications for pelvic lymphadenectomy in prostate cancer.Urol Clin North Am. 2001 Aug;28(3):491-8. doi: 10.1016/s0094-0143(05)70157-9. Urol Clin North Am. 2001. PMID: 11590808 Review.
-
Presence of lymph nodes and metastasis within prostatic anterior fat pad in radical prostatectomy patients: A single Chinese institution experience and literature review.Eur J Surg Oncol. 2023 Dec;49(12):107112. doi: 10.1016/j.ejso.2023.107112. Epub 2023 Oct 10. Eur J Surg Oncol. 2023. PMID: 37832178 Review.
Cited by
-
Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months.ISRN Urol. 2013 May 16;2013:984951. doi: 10.1155/2013/984951. Print 2013. ISRN Urol. 2013. PMID: 23762630 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous